Jens Kristensen

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

Richard Lafayette, Jens Kristensen, Andrew Stone et al. · The Lancet · 2023 · 289 citations · Full text

Medicine, Nephrology, Pharmacology +12

Incidence and clinical epidemiology of necrobacillosis, including Lemierre's syndrome, in Denmark 1990–1995

L. H. Hagelskjær, J. Prag, Jerzy Malczynski et al. · European Journal of Clinical Microbiology & Infectious Diseases · 1998 · 276 citations

Veterinary Medicine, Infectious Diseases, Pathology +5

Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System

Erland J. Erlandsen, Else Randers, Jens Kristensen · Scandinavian Journal of Clinical and Laboratory Investigation · 1999 · 259 citations

Pharmacy, Pharmaceutical Analysis, Biopharmaceutics +12

Intensive, Dynamic Back-Muscle Exercises, Conventional Physiotherapy, or Placebo-Control Treatment of Low-Back Pain

Finn Rolsted Hansen, Tom Bendix, Peder Skov et al. · Spine · 1993 · 232 citations

Medicine, Physical Medicine, Rehabilitation Medicine +17

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 215 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +13